ArticleAJNR. American journal of neuroradiology2015
MRI grading versus histology: predicting survival of World Health Organization grade II-IV astrocytomas.
Article in AJNR. American journal of neuroradiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Imaging features associated with H3 K27-altered and H3 G34-mutant gliomas: a narrative systematic review.Cancer imaging : the official publication of the International Cancer Imaging Society · 2022Pooled it
- Machine Learning Models for Classifying High- and Low-Grade Gliomas: A Systematic Review and Quality of Reporting Analysis.Frontiers in oncology · 2022Pooled it
- Noninvasive Determination ofAJNR. American journal of neuroradiology · 2021Pooled it
- Role of dynamic contrast-enhanced and dynamic susceptibility contrast imaging in evaluating the biological features of glioma.Quantitative imaging in medicine and surgery · 2025Article
- Reply.AJNR. American journal of neuroradiology · 2024Article
- Radiogenomics Provides Insights into Gliomas Demonstrating Single-Arm 1p or 19q Deletion.AJNR. American journal of neuroradiology · 2023Article
- Correlating MRI features with additional genetic markers and patient survival in histological grade 2-3 IDH-mutant astrocytomas.Neuroradiology · 2023Article
- Conventional MRI features can predict the molecular subtype of adult grade 2-3 intracranial diffuse gliomas.Neuroradiology · 2022Article
- Artificial intelligence for multimodal data integration in oncology.Cancer cell · 2022Review
- Noninvasive Determination of the IDH Status of Gliomas Using MRI and MRI-Based Radiomics: Impact on Diagnosis and Prognosis.Current oncology (Toronto, Ont.) · 2022Review
- Primary versus recurrent surgery for glioblastoma-a prospective cohort study.Acta neurochirurgica · 2022Article
- The histological representativeness of glioblastoma tissue samples.Acta neurochirurgica · 2021Article
- DNA methylation profiling for molecular classification of adult diffuse lower-grade gliomas.Clinical epigenetics · 2021Article
- Neuro-Oncology and Radiogenomics: Time to Integrate?AJNR. American journal of neuroradiology · 2020Review
- T2 mapping of molecular subtypes of WHO grade II/III gliomas.BMC neurology · 2020Article
- MRI Features Can Predict 1p/19q Status in Intracranial Gliomas.AJNR. American journal of neuroradiology · 2018Article
- The 2016 revision of the WHO Classification of Central Nervous System Tumours: retrospective application to a cohort of diffuse gliomas.Journal of neuro-oncology · 2018Article
- Computer-assisted brain tumor type discrimination using magnetic resonance imaging features.Biomedical engineering letters · 2018Review
- Preoperative relative cerebral blood volume analysis in gliomas predicts survival and mitigates risk of biopsy sampling error.Journal of neuro-oncology · 2018Article
- The incidence and significance of multicentric noncontrast-enhancing lesions distant from a histologically-proven glioblastoma.Journal of neuro-oncology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeHistologic grading of intracranial astrocytomas is affected by sampling error and substantial inter- and intraobserver variability. We proposed that incorporating MR imaging into grading will predict patient survival more accurately than histopathology alone. MATERIALS AND
methodsPatients with a new diagnosis of World Health Organization grades II-IV astrocytoma or mixed oligoastrocytoma diagnosed between September 2007 and December 2010 were identified. Two hundred forty-five patients met the inclusion criteria. Preoperative MRIs were independently reviewed by 2 readers blinded to the histologic grade, and an MR imaging grade was given. The MR imaging and histopathologic grades were compared with patient survival.
resultsPatients with grade II or III astrocytomas on histology but evidence of necrosis on MR imaging (consistent with a grade IV tumor) had significantly worse survival than patients with the same histology but no evidence of necrosis on MR imaging (P = .002 for grade II histology and P = .029 for grade III). Their survival was not significantly different from that in patients with grade IV tumors on histology (P = .164 and P = .385, respectively); this outcome suggests that all or most are likely to have truly been grade IV tumors. MR imaging evidence of necrosis was less frequent in grade II and III oligoastrocytomas, preventing adequate subgroup analysis.
conclusionsMR imaging can improve grading of intracranial astrocytomas by identifying patients suspected of being undergraded by histology, with high interobserver agreement. This finding has the potential to optimize patient management, for example, by encouraging more aggressive treatment earlier in the patient's course.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.